Daily Stock Analysis, CFRX, ContraFect Corp, priceseries

ContraFect Corp. Daily Stock Analysis
Stock Information
Open
7.12
Close
6.48
High
7.18
Low
6.38
Previous Close
7.09
Daily Price Gain
-0.61
YTD High
13.40
YTD High Date
Jan 13, 2020
YTD Low
4.45
YTD Low Date
May 22, 2020
YTD Price Change
0.68
YTD Gain
11.70%
52 Week High
13.40
52 Week High Date
Jan 13, 2020
52 Week Low
2.69
52 Week Low Date
Aug 29, 2019
52 Week Price Change
1.28
52 Week Gain
24.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 15. 2017
17.50
Mar 1. 2017
20.96
9 Trading Days
19.74%
Link
LONG
Sep 27. 2017
10.20
Oct 11. 2017
11.91
10 Trading Days
16.77%
Link
LONG
Jan 3. 2018
10.30
Jan 17. 2018
11.38
9 Trading Days
10.49%
Link
LONG
Jan 26. 2018
12.50
Feb 9. 2018
14.77
10 Trading Days
18.20%
Link
LONG
May 4. 2018
15.70
Jun 5. 2018
19.05
21 Trading Days
21.31%
Link
LONG
Jun 14. 2018
20.00
Jun 25. 2018
22.34
7 Trading Days
11.69%
Link
LONG
Jul 6. 2018
24.40
Jul 17. 2018
25.83
7 Trading Days
5.85%
Link
LONG
Sep 24. 2018
18.10
Oct 5. 2018
19.81
9 Trading Days
9.42%
Link
LONG
Oct 29. 2018
19.50
Nov 12. 2018
20.82
10 Trading Days
6.76%
Link
LONG
Jun 11. 2019
5.05
Jun 12. 2019
5.33
1 Trading Days
5.45%
Link
LONG
Sep 10. 2019
3.60
Sep 25. 2019
3.84
11 Trading Days
6.69%
Link
LONG
Nov 18. 2019
3.20
Nov 26. 2019
3.50
6 Trading Days
9.63%
Link
LONG
Dec 12. 2019
3.33
Dec 20. 2019
4.02
6 Trading Days
20.77%
Link
LONG
Dec 23. 2019
4.38
Jan 27. 2020
10.21
22 Trading Days
132.93%
Link
LONG
Feb 13. 2020
8.28
Feb 26. 2020
10.21
8 Trading Days
23.28%
Link
LONG
Apr 9. 2020
5.94
Apr 21. 2020
6.33
7 Trading Days
6.48%
Link
LONG
Apr 22. 2020
6.97
Apr 23. 2020
7.36
1 Trading Days
5.60%
Link
LONG
Jun 15. 2020
5.77
Jun 29. 2020
6.64
10 Trading Days
15.00%
Link
Company Information
Stock Symbol
CFRX
Exchange
NasdaqCM
Company URL
http://www.contrafect.com
Company Phone
914-207-2300
CEO
Steven C. Gilman
Headquarters
New York
Business Address
28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY 10701
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001478069
About

ContraFect Corp. is a clinical-stage biotechnology company. It focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. The company scientific and clinical strategy focuses on the use of combination therapies. ContraFect was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.